Related Experiment Video

Updated: Apr 18, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.5K

EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer

Terry W Moody1, Bernardo Nuche-Berenguer, Taichi Nakamura

  • 1NCI, CCR, 9609 Medical Center Drive, Room 2W-130, Bethesda, MD 20892, USA. moodyt@mail.nih.gov.

Current Drug Targets
|January 8, 2015
PubMed

Insights

Targeting G protein-coupled receptors (GPCR) with nonpeptide antagonists may enhance tyrosine kinase inhibitor (TKI) effectiveness in lung cancer patients with wild-type epidermal growth factor receptor (EGFR). This approach shows promise for increasing TKI potency and reducing cancer cell proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer remains a leading cause of cancer mortality worldwide.
  • Tyrosine kinase inhibitors (TKIs) like erlotinib and gefitinib are effective against lung cancer with specific epidermal growth factor receptor (EGFR) mutations.
  • EGFR signaling is crucial for cancer cell proliferation, but resistance mechanisms exist, particularly in tumors with wild-type EGFR.

Purpose of the Study:

  • To investigate methods for enhancing TKI efficacy in lung cancer patients with wild-type EGFR.
  • To explore the role of G protein-coupled receptors (GPCRs) in EGFR transactivation in lung cancer.
  • To evaluate the potential of nonpeptide GPCR antagonists as a therapeutic strategy.

Main Methods:

  • Investigated the mechanism of EGFR transactivation by GPCRs in lung cancer cells.
  • Utilized nonpeptide antagonists targeting specific GPCRs, including bombesin (BB), neurotensin (NTS), and cholecystokinin (CCK).
  • Assessed the impact of these antagonists on lung cancer growth and the cytotoxicity of gefitinib.

Main Results:

  • GPCRs can transactivate wild-type EGFR in lung cancer cells.
  • Nonpeptide antagonists for BB, NTS, and CCK demonstrated inhibitory effects on lung cancer growth.
  • These antagonists also enhanced the cytotoxicity of gefitinib, suggesting a synergistic effect.

Conclusions:

  • GPCR-mediated EGFR transactivation is a significant pathway in lung cancer cell proliferation.
  • Nonpeptide GPCR antagonists represent a promising therapeutic strategy to overcome resistance and improve TKI effectiveness in wild-type EGFR lung cancer.
  • Targeting GPCRs could offer a novel approach to lung cancer treatment.

More Related Videos

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration08:55

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration

Published on: March 17, 2018

23.6K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.4K